Announced
Completed
Financials
Sources
Tags
Minority
medical devices
Acquisition
Israel
Medical Equipment
Single Bidder
Cross Border
Private
Completed
Friendly
Synopsis
Bioventus, which develops and markets orthopedic therapies and diagnostic tools, completed a $15m investment in CartiHeal, an Israel-based developer of the proprietary Agili™-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. "We are pleased Bioventus continues to see value in the Agili-C implant and is making a greater investment to support the completion of the IDE study. We look forward to the work ahead and a successful application for PMA approval," Nir Altschuler, CartiHeal Founder and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.